- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
- Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
- Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
- Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
- Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
- Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
More ▼
Key statistics
On Friday, Alterity Therapeutics Ltd (ATH:ASX) closed at 0.006, -29.41% below its 52-week high of 0.0085, set on Dec 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.006 |
---|---|
High | 0.006 |
Low | 0.0055 |
Bid | 0.005 |
Offer | 0.006 |
Previous close | 0.005 |
Average volume | 19.60m |
---|---|
Shares outstanding | 5.24bn |
Free float | 4.87bn |
P/E (TTM) | -- |
Market cap | 26.19m AUD |
EPS (TTM) | -0.005 AUD |
Data delayed at least 20 minutes, as of Apr 19 2024 06:57 BST.
More ▼